Pharmacokinetics and Safety of a New Parenteral Carbapenem Antibiotic, Biapenem (L-627), in Elderly Subjects

Author:

Kozawa Osamu1,Uematsu Toshihiko1,Matsuno Hiroyuki1,Niwa Masayuki1,Takiguchi Yoshiharu2,Matsumoto Syouzou3,Minamoto Masahiko3,Niida Yoshito3,Yokokawa Masahiro3,Nagashima Satoru4,Kanamaru Mitsutaka4

Affiliation:

1. Department of Pharmacology, Gifu University School of Medicine, Gifu 500,1

2. Department of Clinical Pharmacology, Graduate School of Pharmaceutical Sciences, The Tokushima University, Tokushima 770,2

3. Lederle Japan Ltd., Tokyo 175,3 and

4. Shitoro Clinic, Hamamatsu 432,4 Japan

Abstract

ABSTRACT The pharmacokinetics and tolerability of a new parenteral carbapenem antibiotic, biapenem (L-627), were studied in healthy elderly volunteers aged 65 to 74 years (71.6 ± 2.7 years [mean ± standard deviation], n = 5; group B) and ≥75 years (77.8 ± 1.9 years, n = 5; group C), following single intravenous doses (300 and 600 mg), and compared with those of healthy young male volunteers aged 20 to 29 years (23.0 ± 3.5 years, n = 5; group A). The agent was well tolerated in all three age groups. Serial blood and urine samples were analyzed for biapenem to obtain key pharmacokinetic parameters by both two-compartment model-dependent and -independent methods. The maximum plasma concentration and area under plasma concentration-versus-time curve (AUC) increased in proportion to the dose in all three groups. Statistically significant age-related effects for AUC, total body clearance, and renal clearance (CL R ) were found, while elimination half-life ( t 1/2β ) and percent cumulative recovery from urine of unchanged drug (% UR) remained unaltered ( t 1/2β , 1.51 ± 0.42 [300 mg] and 2.19 ± 0.64 [600 mg] h [group A], 1.82 ± 1.14 and 1.45 ± 0.36 h [group B], and 1.75 ± 0.23 and 1.59 ± 0.18 h [group C]; %UR, 52.6% ± 3.0% [300 mg] and 53.1% ± 5.1% [600 mg] [group A], 46.7% ± 7.4% and 53.0% ± 4.8% [group B], and 50.1% ± 5.2% and 47.1% ± 7.6% [group C]). A significant linear correlation was observed between the CL R of biapenem and creatinine clearance at the dose of 300 mg but not at 600 mg. The steady-state volume of distribution tended to be decreased with age, although not significantly. Therefore, the age-related changes in parameters of biapenem described above were attributable to the combination of decreased lean body mass and lowered renal function of the elderly subjects. However, the magnitude of those changes does not necessitate dosage adjustment in elderly patients with normal renal function for their age.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference17 articles.

1. Adverse effects of monobactams and carbapenem.;Alvan G.;Drug Saf.,1995

2. Effects of age and gender on pharmacokinetics of cefepime

3. Pharmacokinetic studies in elderly people. Are they necessary?;Crome P.;Clin. Pharmacokinet.,1994

4. Crowley J. Echaves S. Cusak B. Vestal R. The elderly Rational therapeutics: a clinical pharmacologic guide for the health professional. Williams R. Brater D. Mordenti J. 1990 141 174 Marcel Dekker Inc. New York N.Y

5. Adult lean body mass declines with age: some longitudinal observations.;Forbes G. B.;Metabolism,1970

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3